Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

2020 KSC/KATRD Guideline for the Diagnosis and Treatment of Pulmonary Hypertension: Executive Summary

  • Received : 2021.02.05
  • Accepted : 2021.06.02
  • Published : 2022.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Pulmonary hypertension (PH) is a condition of increased blood pressure in the pulmonary arteries and is diagnosed with an increased a mean pulmonary artery pressure ≥25 mm Hg. This condition may be associated with multiple clinical situations. Based on pathophysiological mechanisms, clinical presentation, hemodynamic profiles, and treatment strategies, the patients were classified into five clinical groups. Although there have been major advances in the management of PH, it is still associated with significant morbidity and mortality. The diagnosis and treatment of PH have been performed mainly by following European guidelines, even in Korea because the country lacks localized PH guidelines. European treatment guidelines do not reflect the actual status of Korea. Therefore, the European diagnosis and treatment of PH have not been tailored well to suit the needs of Korean patients with PH. To address this issue, we developed this guideline to facilitate the diagnosis and treatment of PH appropriately in Korea, a country where the consensus for the diagnosis and treatment of PH remains insufficient. This is the first edition of the guidelines for the diagnosis and treatment of PH in Korea, and it is primarily based on the '2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.' with the acceptance and adaptation of recent publications of PH.

Keywords

Acknowledgement

We sincerely thank Sun Bok Kang for her dedication and great title illustration. The manuscript was endorsed by Korean College of Rheumatology (KCR), Korean Heart Rhythm Society (KHRS), Korean Pediatric Heart Society (KPHS), Korean Society of Heart Failure (KSHF), Korean Society of Cardiovascular Imaging (KOSCI), Korean Society of Echocardiography (KSE), Korean Society of Interventional Cardiology (KSIC), Korean Society for Transplantation (KST), Korean Society for Laboratory Medicine (KSLM), Korean Pulmonary Hypertension Society in Korean Society of Hypertension (KPHS/KSH), and Korean Association of Clinical Cardiology (KACC).

References

  1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. https://doi.org/10.1093/eurheartj/ehv317
  2. Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, et al. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circ J 2019;83:842-945. https://doi.org/10.1253/circj.cj-66-0158
  3. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888-94. https://doi.org/10.1183/09031936.00145608
  4. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:D42-50. https://doi.org/10.1016/j.jacc.2013.10.032
  5. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019;53:1802148. https://doi.org/10.1183/13993003.02148-2018
  6. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-52. https://doi.org/10.1016/j.jacc.2006.07.061
  7. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81. https://doi.org/10.1056/NEJM199207093270203
  8. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11. https://doi.org/10.1161/CIRCULATIONAHA.104.488486
  9. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913. https://doi.org/10.1183/13993003.01913-2018
  10. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41. https://doi.org/10.1016/j.jacc.2013.10.029
  11. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9. https://doi.org/10.1183/09031936.00092306
  12. Song S, Lee SE, Oh SK, Jeon SA, Sung JM, Park JH, et al. Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: a nationwide study based on the health insurance review and assessment service database. PLoS One 2018;13:e0209148. https://doi.org/10.1371/journal.pone.0209148
  13. Chung WJ, Park YB, Jeon CH, Jung JW, Ko KP, Choi SJ, et al. Baseline characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci 2015;30:1429-38. https://doi.org/10.3346/jkms.2015.30.10.1429
  14. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-S54. https://doi.org/10.1016/j.jacc.2009.04.012
  15. Soubrier F, Chung WK, Machado R, Grunig E, Aldred M, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62:D13-21. https://doi.org/10.1016/j.jacc.2013.10.035
  16. Jang AY, Kim BG, Kwon S, Seo J, Kim HK, Chang HJ, et al. Prevalence and clinical features of bone morphogenetic protein receptor type 2 mutation in Korean idiopathic pulmonary arterial hypertension patients: the PILGRIM explorative cohort. PLoS One 2020;15:e0238698. https://doi.org/10.1371/journal.pone.0238698
  17. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014;46:65-9. https://doi.org/10.1038/ng.2844
  18. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest 2019;155:565-86. https://doi.org/10.1016/j.chest.2018.11.030
  19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70. https://doi.org/10.1093/ehjci/jev014
  20. Taichman DB, McGoon MD, Harhay MO, Archer-Chicko C, Sager JS, Murugappan M, et al. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc 2009;84:586-92. https://doi.org/10.4065/84.7.586
  21. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001;104:429-35. https://doi.org/10.1161/hc2901.093198
  22. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J 2008;32:503-12. https://doi.org/10.1183/09031936.00160307
  23. Thomas CA, Anderson RJ, Condon DF, de Jesus Perez VA. Diagnosis and management of pulmonary hypertension in the modern era: insights from the 6th World Symposium. Pulm Ther 2020;6:9-22. https://doi.org/10.1007/s41030-019-00105-5